Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: blood pressure + drug + telmisartan  Related to the article below (Last Update: 5/5/2008)

New Powerful Antihypertensive Micardisplus 80/25 (80mg Telmisartan ...
PharmaLive.com (press release), PA - Apr 14, 2008
In the TRANSCEND? trial the treatment arms are telmisartan 80mg or placebo ? both on top of standard blood pressure care, not including an ACE or another ...
Mixing blood pressure drugs useless
ScienceAlert, Australia - Apr 6, 2008
This has been further underlined by apparent side-effects such as increased dizziness and blackouts from lower blood pressure, and an increase in kidney ...
Fixed-Dose Combination 80 mg Telmisartan/25 mg Hydrochlorothiazide ...
DG News - Apr 14, 2008
The combination drug was approved for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled by a lower-dose ...
New antihypertensive PritorPlus? 80/25 and Kinzalkomb? 80/25 ...
WebWire (press release), GA - Apr 21, 2008
(1,2) ?For physicians and patients, it is often very challenging to reach the recommended blood pressure targets with the available treatments. ...
Europe Approves New Fixed-Dose Combination Drug for Essential ...
DG News - Apr 21, 2008
... essential hypertension in patients whose blood pressure (BP) is not adequately controlled on 80 mg telmisartan/12.5 mg hydrochlorothiazide (T80/H12.5) ...
Telmisartan May Be an Effective and Safe Alternative to Ramipril ...
DG News - Apr 7, 2008
Compared with the ramipril group, mean blood pressure was lower in both the telmisartan group (-0.9/0.6 mm Hg) and in the combination therapy group ...
Boehringer says hypertension drug Micardis shown to cut risk of ...
Forbes, NY - Apr 7, 2008
... a privately held German drug maker, is trying to get the drug cleared for the prevention of a wide range of heart diseases beyond the blood-pressure ...
Boehringer Ingelheim outpaces the market yet again in 2007
PharmaLive.com (press release), PA - Apr 8, 2008
Telmisartan (Micardis ?) is the first and only angiotensin receptor blocker (ARB) to have proven cardiovascular protective benefits beyond blood pressure ...
Boehringer sails on serenely despite impending Flomax patent expiry
Pharma Times (subscription), UK - Apr 9, 2008
The blood pressure drug Micardis (telmisartan) saw sales of 1.12 billion euros, up 23%, while Flomax/Alna, for the treatment of benign prostatic hyperplasia ...

In order to show you the most relevant results, we have omitted some entries very similar to the 9 already displayed.
If you like, you can repeat the search with the omitted results included.

Source: Google News

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and … -
G Derosa, PD Ragonesi, A Mugellini, L Ciccarelli, … - Hypertens Res, 2004 - ncbi.nlm.nih.gov
Click here to read Effects of telmisartan compared with eprosartan on blood pressure
control, glucose metabolism and lipid profile in hypertensive, type 2 ...

… with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure … -
T Littlejohn, W Mroczek, T Marbury, CP … - Can J Cardiol, 2000 - ncbi.nlm.nih.gov
... These data confirm the long duration of action of telmisartan with consistent and
sustained control of blood pressure over 24 h and during the last 6 h of the ...

… II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure … -
WB White, Y Lacourciere, G Davidai - American Journal of Hypertension, 2004 - Elsevier
... In patients with hypertension, blood pressure (BP) follows a highly ... Telmisartan has
peak plasma levels about 1 h after oral drug administration and a ...

Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously … -
J Wagner, M Drab, J Bohlender, K Amann, W Wienen, … - Clin Exp Hypertens, 1998 - ncbi.nlm.nih.gov
... hypertensive rats by the AT1 receptor antagonist Telmisartan reveals a blood pressure
lowering and reno-protective effect of this drug comparable to other AT1 ...

… of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and …
Y Lacourciere, J Lenis, R Orchard, R Lewanczuk, M … - Blood Press Monit, 1998 - ncbi.nlm.nih.gov
... were well tolerated, however, drug-related edema ... patients administered either
telmisartan or placebo ... CONCLUSIONS: Clinic blood pressure measurements detected no ...

… blood pressure monitoring to evaluate the selective angiotensin II receptor antagonist, telmisartan …
JM Neutel - Blood Press Monit, 2000 - ncbi.nlm.nih.gov
Use of ambulatory blood pressure monitoring to evaluate the selective angiotensin
II receptor antagonist, telmisartan, and other antihypertensive drugs. ...

The 24-hour blood pressure pattern: does it have implications for morbidity and mortality? -
MA Weber - Am J Cardiol, 2002 - ncbi.nlm.nih.gov
... The results of clinical trials using ambulatory blood pressure monitoring have shown
that telmisartan, an angiotensin II receptor antagonist, possesses such ...

Ambulatory Blood Pressure Monitoring to Assess the Comparative Efficacy and Duration of Action of a … -
JM Neutel - 2001 - ingentaconnect.com
... A drug that is well tolerated, can be ... daily, and still provide effective blood pressure
control even if ... Telmisartan, which is a very effective antihypertensive ...

Evaluation of Angiotensin II Receptor Blockers for 24-Hour Blood Pressure Control: Meta-Analysis of … -
JM Neutel, DHG Smith - The Journal of Clinical Hypertension, 2003 - Blackwell Synergy
... Safar ME, Rudnichi A, Asmar R. Drug treatment of hypertension: the reduction of
pulse pressure does not ... parallel that of systolic and diastolic blood pressure. ...

… profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients … -
JM Mallion, JP Siche, Y Lacourciere? - Journal of Human Hypertension, 1999 - nature.com
... also for the 24-h mean blood pressure, telmisartan 40 mg and 80 mg were
significantly (P< 0.05) better than losartan 50 mg. compared ...
-

Source: Google Scholar

Blood Pressure Drug Telmisartan Shows Powerful Activity Against Stroke

 

Drug, Alone or in Combination, Eliminated Stroke Risk, Weill Cornell Team Reports

NEW YORK (Dec. 12, 2007) — Telmisartan, a drug widely used to help control blood pressure, may have uniquely potent activity in preventing stroke, according to a new study conducted in an animal model.

Whether they used the drug alone or in combination with a different type of antihypertensive medication, ramipril, Weill Cornell Medical College researchers found that rats fed a high-salt, stroke-inducing diet were completely protected from the brain attacks while on telmisartan.

"No other study has ever shown complete protection against stroke in this rat model using normal human drug doses" notes study senior author Dr. Daniel F. Catanzaro, professor of physiology and biophysics and professor of physiology in cardiothoracic surgery at Weill Cornell Medical College.

The study, which was funded by telmisartan's German maker, Boehringer Ingelheim Pharma GmbH & Co., is published online in the Journal of the American Society of Hypertension.

Telmisartan (brand name Micardis) is one of a class of widely used antihypertensive drugs known as angiotensin receptor blockers (ARBs). "These drugs primarily act on the vasculature to relax the small blood vessels," Dr. Catanzaro explains.
Telmisartan stands out from other ARBs in that its molecular structure allows it to more easily pass through the blood-brain barrier and enter the brain—something many drugs cannot do.

The new animal study was not constructed to specifically look at telmisartan's effect on stroke. "Because blood pressure is closely related to stroke risk, we really just wanted to look and see if combinations of antihypertensive drugs were better at lowering blood pressure and stroke compared to the use of single agents," Dr. Catanzaro explains.

In this case, his team tested two drugs—telmisartan and an ACE inhibitor, ramipril (Altace)—in a rat model long favored by stroke researchers. In this approach, rats are fed what's known as a "stroke-prone diet," meaning they get lots of salt in both their food and water.

"This rat model has been great at showing us the neuroprotective properties of different drugs in the past, and the results usually correlate with results in humans," Dr. Catanzaro says.

In the study, 25 rats were fed the stroke-prone diet for 8 weeks and received either no medication, telmisartan alone, ramipril alone, or the two drugs together at either full- or half-doses.

"A main finding was that combination therapy did reduce blood pressure the best of any treatment, and it also was best at cutting damage to the rats' hearts and kidneys," Dr. Catanzaro says. "But what was really surprising to us was that any regimen involving telmisartan at doses that would normally be given to humans completely prevented stroke in this model. Most studies with other drugs have used much higher doses and have found only partial protection."

Specifically, 83 percent of rats given no medication showed signs of stroke, as did 56 percent of rats given ramipril alone. However, no strokes were noted in the telmisartan-only or the telmisartan/ramipril combo groups.

Telmisartan's ability to easily pass through the blood-brain barrier (something ramipril cannot do) is likely behind the neuroprotective effect noted in the study, the researchers say.

"Going forward, that's something that we would really like to test out in head-to-head trials pitting telmisartan against other ARBs, for example," Dr. Catanzaro said. "At the same time, we'd like to examine whether telmisartan is actually getting into the brain, or if more peripheral effects—a lowering of blood pressure, for instance—are behind the reduction in stroke."

In the meantime, Boehringer Ingelheim is nearing the end of a major clinical trial looking at the effectiveness of combining telmisartan with ramipril to lower patients' blood pressures and reduce their odds for heart attack and stroke. Dr. Catanzaro's team is not involved in that study.

Co-authors on this study include lead researcher Dr. Ying Zhou, as well as Dr. Fangmin Yu and Dr. Ada R. Ene—all of Weill Cornell Medical College in New York City.


Weill Cornell Medical College


Weill Cornell Medical College—Cornell University's Medical School located in New York City—is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Weill Cornell, which is a principal academic affiliate of NewYork-Presbyterian Hospital, offers an innovative curriculum that integrates the teaching of basic and clinical sciences, problem-based learning, office-based preceptorships, and primary care and doctoring courses. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research in such areas as stem cells, genetics and gene therapy, geriatrics, neuroscience, structural biology, cardiovascular medicine, infectious disease, obesity, cancer, psychiatry and public health—and continue to delve ever deeper into the molecular basis of disease in an effort to unlock the mysteries behind the human body and the malfunctions that result in serious medical disorders. The Medical College—in its commitment to global health and education—has a strong presence in such places as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. With the historic Weill Cornell Medical College in Qatar, the Medical School is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances—from the development of the Pap test for cervical cancer to the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial for gene therapy for Parkinson's disease, the first indication of bone marrow's critical role in tumor growth, and, most recently, the world's first successful use of deep brain stimulation to treat a minimally-conscious brain-injured patient. For more information, visit www.med.cornell.edu.

Powered by Big Medium™

Contact Info
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.